Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $17,601 | $15,558 | $12,729 | $13,533 |
| % Growth | 13.1% | 22.2% | -5.9% | – |
| Cost of Goods Sold | $3,008 | $2,448 | $2,224 | $2,404 |
| Gross Profit | $14,593 | $13,110 | $10,504 | $11,129 |
| % Margin | 82.9% | 84.3% | 82.5% | 82.2% |
| R&D Expenses | $4,121 | $3,336 | $2,734 | $3,023 |
| G&A Expenses | $2,741 | $2,648 | $2,362 | $2,309 |
| SG&A Expenses | $2,741 | $2,648 | $2,362 | $2,309 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,862 | $5,984 | $5,096 | $5,331 |
| Operating Income | $7,730 | $7,126 | $5,408 | $5,798 |
| % Margin | 43.9% | 45.8% | 42.5% | 42.8% |
| Other Income/Exp. Net | -$498 | -$350 | -$1,952 | -$759 |
| Pre-Tax Income | $7,232 | $6,776 | $3,456 | $5,039 |
| Tax Expense | $1,650 | $1,116 | $697 | $629 |
| Net Income | $5,583 | $5,661 | $2,759 | $4,410 |
| % Margin | 31.7% | 36.4% | 21.7% | 32.6% |
| EPS | 6.22 | 6.3 | 3.07 | 4.91 |
| % Growth | -1.3% | 105.2% | -37.5% | – |
| EPS Diluted | 6.21 | 6.29 | 3.06 | 4.88 |
| Weighted Avg Shares Out | 897 | 898 | 898 | 898 |
| Weighted Avg Shares Out Dil | 899 | 900 | 901 | 903 |
| Supplemental Information | – | – | – | – |
| Interest Income | $65 | $40 | $48 | $44 |
| Interest Expense | $180 | $249 | $244 | $225 |
| Depreciation & Amortization | $470 | $479 | $463 | $485 |
| EBITDA | $7,882 | $7,504 | $4,163 | $5,748 |
| % Margin | 44.8% | 48.2% | 32.7% | 42.5% |